BioSpace News Archive

Lexaria Bioscience Corp., a global innovator in oral drug delivery platforms, is pleased to outline its planned strategic initiatives for 2021 with a sharply enhanced focus on solutions related to the regulated pharmaceutical and medical market segments where it believes its patented technology will offer the highest value and utility.

Updated results will be presented from ASPEN-01, the phase 1b study of ALX148 in combination with rituximab in patients with relapsed/refractory non-Hodgkin lymphoma (“NHL”)

Third Quarter TIBSOVO® Net Revenue of $31.7 Million; Company Narrows 2020 TIBSOVO® Net U.S. Revenue Guidance to $113–115 Million

Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia IMR-687 g rant ed Orphan Drug d esignation from European Commission for sickle cell disease Company to host conference call and live webcast today at 8:30 a.m. ET BOSTON, Nov. 05, 2020

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the following upcoming investor conferences: The Investor Summit Group’s Virtual Fall Summit, which is being held from November 16th - 18th. Management will present on Tuesday, November 17th at 1:00 p.m. Eastern Time. Alliance Global Partners’ Vir

NeuroRx, Inc. and Relief Therapeutics Holdings AG announced that the independent Data Monitoring Committee met yesterday and voted unanimously that NCT 04311697 should continue as planned to its full enrollment of 165 patients.

CENTOGENE expands its SARS-CoV-2 testing solution to Berlin Brandenburg Airport (BER) after successfully launching COVID-19 test centers at three major German airports in cooperation with Lufthansa

Total Revenue Increased 39% in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared toSame Periods of 2019 Despite COVID-19 Headwinds

$344.9 million in cash, cash equivalents and investment securities expected to fund multiple milestones, including progressing KarXT to NDA submission, and operations for at least the next three years

Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2020.